Manifaxine

Manifaxine (GW-320,659) is a drug developed by GlaxoSmithKline through structural modification of radafaxine, one of the major active metabolites of bupropion. It acts as a norepinephrine-dopamine reuptake inhibitor (NDRI). It was researched for treatment of ADHD and obesity and was shown to be safe, reasonably effective and well tolerated for both applications,[1][2] but no results have been reported following these initial trials and its current status is unclear.

Manifaxine

Clinical data
ATC code	none
Identifiers
IUPAC name (2S,3S,5R)-2-(3,5-difluorophenyl)-3,5-dimethylmorpholin-2-ol
CAS Number	135306-39-7^Y
PubChem CID	60829
ChemSpider	54816^N
UNII	J8IE53G2IV
CompTox Dashboard (EPA)	DTXSID60928953
Chemical and physical data
Formula	C12H15F2NO2
Molar mass	243.254 g·mol^−1
3D model (JSmol)	Interactive image
SMILES C[C@@H]1CO[C@]([C@@H](N1)C)(C2=CC(=CC(=C2)F)F)O
InChI InChI=1S/C12H15F2NO2/c1-7-6-17-12(16,8(2)15-7)9-3-10(13)5-11(14)4-9/h3-5,7-8,15-16H,6H2,1-2H3/t7-,8+,12-/m1/s1^N Key:OZGPVYJHWWPEFT-RGNHYFCHSA-N^N
^NY (what is this?)  (verify)

See also

• Phenmetrazine
• Radafaxine
• Hydroxybupropion
• G-130
• 2-Phenyl-3,6-dimethylmorpholine

References

1. DeVeaugh-Geiss J, Conners CK, Sarkis EH, Winner PK, Ginsberg LD, Hemphill JM, et al. (August 2002). "GW320659 for the treatment of attention-deficit/hyperactivity disorder in children". Journal of the American Academy of Child and Adolescent Psychiatry. 41 (8): 914–20. PMID 12162627.
2. Spraggs CF, Pillai SG, Dow D, Douglas C, McCarthy L, Manasco PK, et al. (December 2005). "Pharmacogenetics and obesity: common gene variants influence weight loss response of the norepinephrine/dopamine transporter inhibitor GW320659 in obese subjects". Pharmacogenetics and Genomics. 15 (12): 883–9. PMID 16272960.